In Vitro Evaluation and Mitigation of Niclosamide’s Liabilities as a COVID-19 Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines10081284
Abstract: Niclosamide, an FDA-approved oral anthelmintic drug, has broad biological activity including anticancer, antibacterial, and antiviral properties. Niclosamide has also been identified as a potent inhibitor of SARS-CoV-2 infection in vitro, generating interest in its use… read more here.
Keywords: cell; mitigation niclosamide; sars cov; vitro evaluation ... See more keywords